Abstract: Sunscreen compositions comprising a dermatologically acceptable carrier and a polyhydroxy fullerene compound are described. The sunscreen compositions can be used to protect a substrate such as the skin of a subject from the effects of ultraviolet radiation.

Abstract: The present invention provides a functional food that utilizes health-promoting effects of charcoal, is readily ingested, has no adverse side effect, and has an effect of improving and repressing obesity. The functional food includes a charcoal composition having at least one of a bamboo charcoal, a Bincho charcoal, an activated bamboo charcoal and an activated Bincho charcoal, and both of the activated bamboo charcoal and the activated Bincho charcoal have a bulk density of 0.3 to 0.6 g/ml, an average particle size of 10 ?m or smaller, a BET specific surface area of 1000 to 1200 m2/g, and an iodine adsorption amount of 1000 to 1300 mg/g.

Abstract: A method for treating a person's skin is disclosed. The method includes topically applying to the skin a composition comprising from 0.001% to 20% by weight of an aqueous, alcoholic, or aqueous-alcoholic extract from a plant extract.

Abstract: Methods for producing a cross-linkable rubber composition that comprises a masterbatch are disclosed. The masterbatch comprising a base masterbatch and the method includes forming the base masterbatch by adding a diene rubber to an internal mixer; adding a total quantity of a solid agglomerated material that includes carbon nanotubes into the mixing chamber; and mixing the diene elastomer and the solid agglomerated material. To ensure adequate distribution and dispersion of the material, the base masterbatch has a minimum Mooney viscosity ML(1+4)100 of at least 85 MU.

Abstract: A water-insoluble fullerene is at least partially dissolved in a biocompatible lipid carrier, especially a fat or an oil such as butter, olive oil, and liquid paraffin. When administered to mammals, the fullerene, most preferably [60]fullerene dissolved in olive oil, scavenges free radicals and prolongs life span in rats.

Abstract: Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells.

Abstract: The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, ca

Abstract: Oral hygiene compositions including pharmacologically active ingredients extracted from one or more species of plants (or interbred strains thereof) in the Cannabis genus. In an embodiment, an extraction process may include techniques to maximize the ratio of tetrahydrocannabinolic acid (“THCA”) to tetrahydrocannabinaol (THC) in the essential oil extract, in order to maximize the presence of the non-euphoric THCA. In an embodiment, a mouthwash composition is provided. In an embodiment, an essential oil extract may be applied neat. In an embodiment, an essential oil extract may be mixed with food grade carriers (e.g. glycerol, or vegetable oil) and/or diluents (e.g. water, ethanol), and used as mouth rinse, in a conventional rinse and spit fashion. In an embodiment, an essential oil extract may be mixed with food grade carries and/or diluents and used as an ingestible composition, in a rise and swallow fashion.

Abstract: The present invention relates to non-aerosol shaving compositions which are free of propellants, and methods of preparing and using such shaving composition. In particular, the present invention relates to a non-aerosol, propellant-free composition comprising: (i) at least two C14 to C16 carboxylic acids or an alkali metal salt thereof; (ii) at least one compound of general Formula (I) R—O—[—CH2CH2O—]n—CH2CO2H??(I) or an alkali metal salt thereof, wherein R represents a saturated, straight- or branched-chain C10 to C18 alkyl group; and n represents an integer between 4 and 12; (iii) polyvinyl pyrrolidone; and (iv) water.

Abstract: A method for styling hair comprising: —applying to hair a hair treatment composition comprising from 4 to 25 wt % a citric or aconitic acid and having a pH of from 1 to 3; —leaving the product on the hair for from 5 to 90 minutes; —rinsing the product from the hair; and —styling.

Abstract: A method for producing charcoal particles or pellets which use different additives as binders for the biochar pellets. The method includes producing a mixture with charcoal and additives selected from nanocrystalline cellulose, nanocrystalline fibrils, bentonite, and polyvinyl acetate. The mixture is created by mixing one or more of the additives with charcoal or bentonite. The mixture is then processed in a pelletizer device. While processing, the surface of the mixture is sprayed with a liquid. Once turned into pellets by way of the pelletizer device, the resulting pellets are then dried by applying heat to the pellets. The liquid can be water or a solution of water and sodium borate.

Abstract: A cosmetic composition including an Osmanthus asiaticus extract and a Clematis apiifolia extract as active ingredients is provided.

Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

Abstract: Provided is a capacitor in which, even in the case of a high maximum charging voltage, decomposition of the electrolyte can be suppressed and charging and discharging can be performed with stability. The capacitor includes a positive electrode containing a positive-electrode active material, a negative electrode containing a negative-electrode active material, a separator disposed between the positive electrode and the negative electrode, and an electrolyte, wherein the positive-electrode active material contains a porous carbon material, in a volume-based pore size distribution of the porous carbon material, a cumulative volume of pores having a pore size of 1 nm or less accounts for 85% or more of a total pore volume, the porous carbon material has a crystallite size of 1 to 10 nm, the porous carbon material contains an oxygen-containing functional group, and a content of the oxygen-containing functional group is 3.3 mol % or less.

Abstract: In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA,GLU,ASP,GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may include carnosine or camatine. In some embodiments, the chemical composition may include at least one lipid. One or more components of the chemical composition may be suspended in and/or dissolved in the at least one lipid. At least one lipid may include olive oil or mussel oil. In some embodiments, a method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation comprising the chemical composition. The method may include inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation. In some embodiments, the subject may include a human or a nonhuman mammal. Nonhuman mammals may include equines, canines, or felines.

Abstract: A macroparticle pigment powder and methods of making the same. The macroparticle pigment powder comprises a plurality of macroparticle particles. The macroparticles are comprised of a matrix material that include pigment particles. In some embodiments the matrix material is polymeric in nature and selected from the group consisting of a natural latex, acrylics, polyacrylate, polymethacrylate, polyurethane, polyvinyl acetate, styrene-butadiene rubber, acrylonitrile butadiene styrene copolymer, and combinations thereof.

Abstract: A pharmaceutical composition for treating urinary system disorders includes a carbon material carried by a water-containing carrier and having a carbon content over 60 percentage by weight (wt %), such that both of the carbon material and the water-containing carrier constitute a pharmaceutically acceptable water-containing carrier carrying the carbon material, and the carbon material falls within a range of 0.1 mg/ml to 500 mg/ml per unit dose and has a diameter from 2 nm to 2 mm, such that the pharmaceutical composition is capable of reducing symptoms of cystitis by contacting the carbon material with a bladder or related tissues of the bladder in an animal body.

Abstract: The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations.

Abstract: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m2/g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g, is disclosed.

Abstract: A method for treating urinary system disorders comprising: a pharmaceutical composition comprising a carbon material and a water-containing carrier, the pharmaceutical composition comprising a carbon material in an amount from 0.001 mgs to 100 mgs, both of the carbon material and the water-containing carrier constitute a pharmaceutically acceptable water-containing carrier carrying the carbon material, and the carbon material having a diameter falling within a range from 2 nm to 2 mm; Then instilled this pharmaceutical composition into the bladder for adsorb LPS of bacteria, aqueous vehicle in a volume of from 50 mL to 700 mL. After adsorb, discharging the LPS together with urine out of cystitis patients. This method is capable of reducing symptoms of cystitis by contacting the carbon material with a bladder or related tissues of the bladder in an animal body.

Abstract: Methods of managing and treating a keloid in mammal are disclosed. An embodiment includes managing and treating a keloid by covering the keloid with flurandrenolide tape, applying graphites ointment on the keloid and applying witch hazel ointment on the keloid. A further embodiment includes covering the keloid with flurandrenolide tape; and removing the flurandrenolide tape from the keloid after 5 to 10 hours; and applying witch hazel ointment on the keloid; and applying capsaicin ointment on the keloid. Yet another embodiment comprises steps of making and providing a mixture including equal proportions by mass (or weight) of flurandrenolide, witch hazel, graphites and capsaicin; and applying the mixture on the keloid in a manner that includes covering the keloid with the mixture.

Abstract: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, a bulk density is less than 0.54 g/mL, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.9 meq/g is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably reducing an amount of urinary proteins excretion.

Abstract: Polymeric fibers and films that incorporate IR-emitting materials are disclosed. These fibers and films can be loaded with higher concentrations of IR-emitting materials than was previously thought possible. The IR emissivity of the resulting polymeric materials can be enhanced by increasing the surface area of these fibers and films. Laminates of the fibers or films with other substrate layers are also disclosed.

Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.

Abstract: The present invention concerns means and methods for predicting the risk of a subject to suffer from liver damage. In particular, it pertains to a method for predicting the risk of a subject to suffer from liver damage caused by acetaminophen comprising determining the amount of putrescine in a blood, serum or plasma sample that has been obtained from the subject after administration of acetaminophen, and comparing the determined amount to a reference, whereby the risk of the subject to suffer from liver damage caused by acetaminophen is predicted. Also provided are devices for carrying out the aforementioned methods.

Abstract: An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O2 directly (CDC OC), or hemoglobin can be adsorbed to provide a hemoglobin-based oxygen carrier (CDC HBOC). The delivery system allows the use of a variety of hemoglobins which differ in their oxygen dissociation profiles, including variant and mutant hemoglobins from other species. The delivery system is biocompatible and stable, and is able to irreversibly bind and hold large amounts of functional hemoglobin variants. The CDC HBOC and CDC OC provide a safe and effective blood substitute for combat casualty care, as well as being useful for oxygen delivery in other contexts.

Abstract: A water-insoluble fullerene is at least partially dissolved in a biocompatible lipid carrier, especially a fat or an oil such as butter, olive oil, and liquid paraffin. When administered to mammals, the fullerene, most preferably [60]fullerene dissolved in olive oil, scavenges free radicals and prolongs life span in rats.

Abstract: Contaminants are filtered from a fluid flow stream and the filter is regenerated by a process including steps of: providing a filter material comprising both carbon and potassium iodide; passing a contaminated fluid stream in contact with the filter material; adsorbing contaminants from the fluid stream onto surfaces in the filter material; passing an electric current through the filter material with adsorbed contaminant thereon; disassociating contaminant from the surfaces of the filter material; and removing disassociated contaminant from the filter material by carrying away the disassociated contaminant in a fluid flow mass. Separately, a stable, active iodine solution is also provided for numerous deodorizing and disinfecting applications.

Abstract: A method for producing biochar particles or pellets which use sulphur and other additives. The method includes producing a mixture with biochar and additives selected from sulphur, lignin, and gluten. The mixture is mixed with water and passed through an extruder to produce an extrudate. The extrudate is then cut into pellets. The pellets are then tumbled/spun with each other and heated to result in mostly spheroidal pellets whose mechanical characteristics allow them to be used with well-known agricultural equipment. The biochar can be produced with sulphur incorporated as an outer coating. To produce this sulphur coated biochar, the method includes feeding a biomass feedstock to a pyrolysis reactor, pyrolyzing the feedstock into biochar particles, size-sorting the biochar particles, and coating the biochar particles with the sulphur coating material.

Abstract: The object of the present invention is to provide an adsorbent for oral administration, which can: obviate sandy texture of granules-formed adsorbent for oral administration, reduce the volume administered compared to encapsulated adsorbent for oral administration, and be easy to take.

Abstract: A derivatized poly(ester amide) (D-PEA) and coatings and medical devices formed therefrom are provided. The coatings and medical devices may optionally include a biobeneficial material and/or a biocompatible polymer and/or a bioactive agent. The medical devices can be implanted in a patient to treat, prevent, or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Abstract: The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective amount of charcoal.

Abstract: Composite materials comprising functionalized graphenes, methods of preparing the composite materials, and methods of using the composite materials are described herein. A composite material comprising reduced graphene oxide, chitosan, and native lactoferrin show much higher antimicrobial activity versus individual reduced graphene oxide, chitosan, and native lactoferrin alone.

Abstract: A phase change formulation includes a reversible phase change material and a thermal conductivity additive formulated for application to a user's epidermis.

Abstract: A transdermal delivery device for treating or preventing scars, such as stretch marks, comprising a composition comprising vitamin E, hyaluronan, biotin, Rosmarinus officinalis, collagen, and a heat generating ingredient, and methods therefor.

Abstract: The methods for treatment using an adsorbent having a high adsorbability, and capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.

Abstract: The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective.

Abstract: The present invention relates to cosmetic make-up compositions, in particular mascaras, comprising carbon black encapsulated in a spherical silica matrix. These compositions are characterized by a deep and glossy black color.

Abstract: A method for preventing or treating a brain nervous disease includes administering to a subject in need thereof a therapeutically effective amount of a carbon nanotube, wherein the nervous disease is a brain disease or a traumatic central nervous system injury. The composition of the present invention enables patients to recover from physical damage to the brain, exhibits superior efficacy for inhibiting the onset of Parkinson's disease and strokes in animal models for Parkinson's disease and strokes, and the cytotoxic effects of beta amyloid in beta amyloid toxicity tests. Therefore, the composition of the present invention can be effectively used in the preparation of medicine for protecting cranial nerves, therapeutic agents for preventing or treating brain disease, or therapeutic agents for treating traumatic injuries to the central nervous system.

Abstract: The invention relates to the use of a particulate active carbon, in particular in the form of active carbon particles, preferably active carbon beads, for the field of medicine and/or for the production of a medicament, wherein the active carbon employed has a large micropore volume content, based on the total pore volume of the active carbon. A microporous active carbon of this type if particularly suitable for medicinal use.

Abstract: The methods for treatment using an adsorbent having a high adsorbability, and capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.

Abstract: Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site.

Abstract: An adsorbent for an oral administration, comprising a spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.

Abstract: A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.

Abstract: The composition for the treatment of ulcers includes ground charcoal, ground mustard seed and an edible salt dissolved or suspended in an edible oil. A single effective therapeutic dosage of the composition includes approximately 4,000 mg of the ground charcoal, approximately 2,500 mg of the ground mustard seed, approximately 550 mg of the edible salt, and approximately 15 ml of the edible oil. The effective therapeutic dosage is delivered to the patient orally, and may be provided to the patient as a tablet or capsule, or as a liquid mixture.

Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.

Abstract: The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.

Abstract: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, a bulk density is less than 0.54 g/mL, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.9 meq/g is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably reducing an amount of urinary proteins excretion.

Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.

Abstract: An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, and a diffraction intensity ratio, an R value, determined by an equation (1): R=(I15?I35)/(I24?I35)??(1) wherein I15 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 15°, I35 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 35°, and I24 is a diffraction intensity when a diffraction angle (2?) of an X-ray diffractometry is 24°, is 1.4 or more; and an adsorbent for an oral administration, characterized by comprising a surface-modified spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m2/g or more, a total amount of acidic groups is 0.40 to 1.00 meq/g, a total amount of basic groups is 0.40 to 1.